

DNDi at ECTMIH 2017

Tuesday, October 17th

🕒 13:30 – 15:00 → Venue: Darwin

DNDi's session

Phase II/III results for fexinidazole, the first oral treatment for human African trypanosomiasis (HAT)

Organizer: Nathalie Strub-Wourgaft, Medical Director, Drugs for Neglected Diseases *initiative* (DNDi)

Chair: José Ramon Franco, NTD department, WHO

Speakers:

• Introduction

José Ramon Franco, NTD department, WHO

• Developing treatments for sleeping sickness: DNDi's R&D strategy

Nathalie Strub-Wourgaft, Medical Director, DNDi

• Results from the pivotal trial of fexinidazole: non-inferiority shown to the gold standard NECT

Antoine Tarral, Head of HAT clinical programme, DNDi

• The efficacy of fexinidazole in children and stage 1 patients

Clélia Bardonneau, Senior Clinical Project Manager, DNDi

• Film: 'The Last Mile'

• Structured discussion 1: Working together across continents to organize and run clinical trials in remote areas

Wilfried Mutombo Kalonji, Project Coordinator HAT, DNDi

Olaf Valverde Mordt, Medical Manager HAT, DNDi

• Structured discussion 2: The potential impact of fexinidazole on the global strategy to eliminate sleeping sickness

Crispin Lumbala, Director, PNLTHA, DRC

Pere Perez Simarro, HAT Access Advisor, DNDi



Poster session

• Clinical mentoring via mobile teams – a new approach to visceral leishmaniasis care in resource constrained settings in Africa

den Boer M, Herrero M, Lado M, Atiaby A, Ochol D, Adera C, Alvar J, Mekonen B, Ritmeijer K

• Screening the pathogen box and the stasis box to identify compounds inhibiting *Madurella mycetomatis* growth *in vitro* and *in vivo*

Lim W, Konings M, Melse Y, Todd M, Perry B, Ioset JR, van de Sande W



Wednesday, October 18th

Oral presentation with a DNDi author

🕒 15:30 → Venue: Toucan

Hepatitis C care in resource-constrained settings – Do we have a scalable public health approach anno 2017?

- The innovative R&D model of the Drug for Neglected Diseases *initiative* (DNDi) to increase access to HCV care in low- and middle-income countries
Andrieux-Meyer I

Poster session

- The Human African Trypanosomiasis (HAT) Platform
Mbo F, Valverde O
- Is long lasting insecticide treated bed net able to reduce visceral leishmaniasis incidence? The evidence in Bangladesh
Chowdhury R, Chowdhury V, Faria S, Dash AP, Bhattacharya SK, Akter S, Akhter S, Argaw D, Bern C, Alvar J, Banu Q
- Projected number of people with onchocerciasis-loiasis co-infection in Africa, 1995-2025
Vinkes Melchers NVS, Tekle AH, Coffeng LE, Pion SDS, Zouré HGM, Pedrique B, Boussinesq M, Wanji S, Remme JHF, Stolk WA

Thursday, October 19th

Oral presentations with a DNDi co-author

🕒 15:30 → Venue: Toucan

Kala-azar elimination in the Indian subcontinent

- *Phlebotomus argentipes* Sand Fly control in Bangladesh: A cluster randomized controlled trial
Chowdhury R, Faria S, Huda MM, Chowdhury V, Mondal D, Akhter S, Akter S, Nabi SG, Kroeger A, Argaw D, Alvar J

🕒 17:00 → Venue: Toucan

International Partnerships and Collaboration

- Building a visceral leishmaniasis data-sharing platform to optimize treatment and inform future research
Guerin PJ, Otieno M, Alvar J, on behalf of the IDDO VL data platform


Poster session


- Visceral leishmaniasis treatment access – The reality on the ground in Sudan
Atiaby A, Alkhatim SS, Elhag MS, Herrero M, Paintain L, Webster J, Alvar J, Ritmeijer K, den Boer M


DNDi

Drugs for Neglected Diseases *initiative*

15 Chemin Louis-Dunant – 1202 Geneva
Switzerland
Tel: +41 22 906 9230
Fax: +41 22 906 9231
dndi@dndi.org
www.dndi.org


 facebook.com/dndi.org

 twitter.com/dndi

 instagram.com/drugsforneglecteddiseases

 linkedin.com/company/dndi

 youtube.com/dndiconnect

 Subscribe to DNDi's newsletter:
www.dndi.org/newsletter